Bicara Therapeutics financials
$18.56−1.28%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | -$60.0M | -$60.2M | -$41.1M | -$40.7M | -$32.0M | -$41.8M | -$26.6M | -$20.6M |
| Net income | -$55.4M | -$56.2M | -$37.4M | -$36.3M | -$27.4M | -$36.8M | -$21.0M | -$17.5M |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.82 | $-0.93 | $-0.68 | $-0.67 | $-0.50 | $-0.68 | $-0.38 | $-1.60 |
| EBITDA | -$59.9M | -$60.2M | -$41.1M | -$40.7M | -$32.0M | -$41.8M | -$26.6M | -$20.6M |
| Operating cash flow | -$44.2M | -$37.5M | -$23.9M | -$29.2M | -$25.6M | -$28.1M | -$30.0M | -$17.2M |
| Free cash flow | -$44.3M | -$37.6M | -$24.1M | -$29.3M | -$25.6M | -$28.1M | -$30.1M | -$17.2M |
| Diluted shares | 67.9M | 60.7M | 55.1M | 54.6M | 54.5M | 54.5M | 54.8M | 10.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $96.6M | $323.5M | $96.7M | $171.7M | $436.6M | $462.1M |
| Short-term investments | $400.7M | $216.3M | $318.1M | $118.5M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $512.2M | $553.6M | $431.0M | $424.7M | $453.6M | $478.1M |
| Total liabilities | $43.5M | $39.6M | $29.5M | $21.9M | $18.4M | $19.1M |
| Shareholders' equity | $468.8M | $514.0M | $401.5M | $402.8M | $435.2M | $459.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology